Podchaser Logo
Home
Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Released Friday, 15th July 2022
Good episode? Give it some love!
Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Friday, 15th July 2022
Good episode? Give it some love!
Rate Episode

In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process.Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236

(1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features